Who are Carac Cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, SOX plus PD-1 inhibitor, 5Fluorouracil, Intrathecal injection of pemetrexed.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carac-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Carac Cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carac Cream (Carac Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite, topical chemotherapy. Area: Dermatology/Oncology.

phase 3 Antimetabolite, topical chemotherapy Thymidylate synthase Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Carac Cream (Carac Cream) — Wake Forest University Health Sciences. Carac Cream is a topical formulation of fluorouracil that inhibits thymidylate synthase to disrupt DNA synthesis in rapidly dividing cells, particularly actinic keratosis lesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carac Cream TARGET	Carac Cream	Wake Forest University Health Sciences	phase 3	Antimetabolite, topical chemotherapy	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
SOX plus PD-1 inhibitor	SOX plus PD-1 inhibitor	Liaoning Cancer Hospital & Institute	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); S-1 (thymidylate synthase/5-FU metabolism); oxaliplatin (DNA cross-linking)
5Fluorouracil	5Fluorouracil	University of Nebraska	marketed	Antimetabolite	Thymidylate synthase
Intrathecal injection of pemetrexed	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite, topical chemotherapy class)

Wake Forest University Health Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carac Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/carac-cream. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing